Latest stories on ELTX
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Business Insider56 · neutralgeneral
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Business Insider56 · neutralgeneral
Elicio Therapeutics stock price target reiterated at $23 by H.C. Wainwright
Investing.com Analyst Ratings56 · neutralanalyst
Elicio Therapeutics reports Q2 EPS (43c), consensus (54c)
The Fly34 · bearishearnings
Elicio Therapeutics GAAP EPS of -$0.43 beats by $0.11
Seeking Alpha56 · neutralearnings
Elicio Therapeutics, Inc. (ELTX) files 8-K
SEC 8-K50 · neutralgeneral
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
GlobeNewswire32 · bearishearnings
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
StockTitan28 · bearishearnings
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
Business Insider59 · neutralproduct/pr
Elicio Therapeutics Faces Investor Scrutiny as Lawsuit Investigation Follows Failed Phase 2 Study
July 8, 2026
MarketChameleon28 · bearishgeneral
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering | ELTX Stock News
StockTitan24 · bearishgeneral
Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment
Stocktwits News28 · bearishgeneral
Elicio Therapeutics, Inc. (ELTX) files 8-K
SEC 8-K50 · neutralgeneral
Elicio Therapeutics drops 5%, prices $15M registered direct offering
Seeking Alpha28 · bearishgeneral
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering | ELTX Stock News
StockTitan28 · bearishgeneral
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes | ELTX Stock News
StockTitan63 · neutralgeneral
Elicio Highlights ELI-002 7P Progress in Pancreatic Cancer
TipRanks63 · neutralproduct/pr
Elicio Therapeutics, Inc. (ELTX) files 8-K
SEC 8-K50 · neutralgeneral
ELTX Investigation Follows 72% Stock Collapse After Phase 2 Trial Misses Key Endpoint
MarketChameleon19 · bearishgeneral
Elicio Highlights Promising Synergy With Checkpoint Inhibitor Therapy
TipRanks67 · bullishproduct/pr
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints
Stocktwits News22 · bearishearnings
ELTX Refines Phase 3 Strategy After Targeted Pancreatic Cancer Therapy Shows Promise in Key Patient Subgroup
MarketChameleon58 · neutralproduct/pr
Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan
TipRanks67 · bullishproduct/pr